TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING USAGE OF SYNTHESIZED OLIGOS IN MOLECULAR DIAGNOSTICS AND CLINICAL APPLICATIONS
3.1.2 INCREASING GOVERNMENT INVESTMENTS, R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
3.2 GENETIC DISORDERS
3.3 RESTRAINTS
3.3.1 LACK OF SKILLED PROFESSIONALS
3.3.2 INCREASING IN-HOUSE PRODUCTION HINDERING THE NORTH AMERICA MARKET GROWTH
3.4 OPPORTUNITIES
3.4.1 STRATEGIC INITIATIVES OF THE MARKET PLAYERS
3.5 DEVELOPMENTS AND INNOVATIONS OF NEW PRODUCTS
3.6 CHALLENGES
3.6.1 STRINGENT REGULATIONS
3.6.2 DRUG DELIVERY & TOXICOLOGY CHALLENGES
4 EXECUTIVE SUMMARY
4.1 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
5 PREMIUM INSIGHTS
6 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 DNA OLIGONUCLEOTIDES
6.3 RNA OLIGONUCLEOTIDES
7 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OLIGONUCLEOTIDE-BASED DRUGS
7.3 PRIMERS
7.4 PROBES
7.5 INTERMEDIATE-SCALE SYNTHESIZED OLIGOS
7.6 LARGE-SCALE SYNTHESIZED OLIGOS
7.7 LINKERS & ADAPTORS
7.8 ARRAY-BASED OLIGOS
8 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY CONSUMABLES
8.1 OVERVIEW
8.2 INSTRUMENTS
8.3 KITS & REAGENTS
8.4 OTHERS
9 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SERVICE TYPE
9.1 OVERVIEW
9.2 CUSTOM OLIGOS
9.2.1 MODIFICATION
9.2.2 PURIFICATION
9.3 PREDESIGNED OLIGOS
9.4 OLIGO SYNTHESIS
9.4.1 0 NMOL
9.4.2 5,000 NMOL
9.4.3 -200 NMOL
9.4.4 -50 NMOL
9.4.5 000 NMOL
9.4.6 MORE THAN 10,000 NMOL
10 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 RESEARCH APPLICATIONS
10.2.1 PCR
10.2.2 QPCR
10.2.3 SEQUENCING
10.2.4 GENE SYNTHESIS
10.2.5 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
10.2.6 DNA MICROARRAYS
10.2.7 OTHER APPLICATIONS
10.3 THERAPEUTIC APPLICATIONS
10.3.1 DNA & ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES
10.3.2 RNAI OLIGONUCLEOTIDE-BASED THERAPIES
10.3.3 CPG OLIGONUCLEOTIDE-BASED THERAPIES
10.3.4 OTHERS
10.4 DIAGNOSTIC APPLICATIONS
10.5 OTHERS
11 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER
11.1 OVERVIEW
11.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3 ACADEMIC & RESEARCH INSTITUTES
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.5 HOSPITALS
11.6 OTHERS
12 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET, BY GEOGRAPHY
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT & DBMR ANALYSIS
15 COMPANY PROFILE
15.1 DANAHER
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENEUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 MERCK KGAA
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 SERVICE PORTFOLIO
15.2.5 PRODUCT PORTFOLIO
15.2.6 RECENT DEVELOPMENT
15.3 GENERAL ELECTRIC
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENEUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THERMO FISHER SCIENTIFIC INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 SERVICE PORTFOLIO
15.4.5 PRODUCT PORTFOLIO
15.4.6 RECENT DEVELOPMENTS
15.5 AGILENT TECHNOLOGIES, INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 EUROFINS SCIENTIFIC
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 COMPANY SHARE ANALYSIS
15.6.4 SERVICE PORTFOLIO
15.6.5 RECENT DEVELOPMENTS
?
15.7 ATDBIO LTD.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 SERVICE PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 AJINOMOTO CO.,INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BIANOSCIENCE GMBH
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.10 BIO BASIC INC
15.10.1 COMPANY SNAPSHOT
15.10.2 SERVICE PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 BIOLYTIC LAB PERFORMANCE INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 BIO-SYNTHESIS INC
15.12.1 COMPANY SNAPSHOT
15.12.2 SERVICE PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 GENSCRIPT
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENEUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 KANEKA EUROGENTEC S.A.
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 SERVICE PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 LGC LIMITED
15.15.1 COMPANY SNAPSHOT
15.15.2 SERVICE PORTFOLIO
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENTS
15.16 NITTO DENKO CORPORATION
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 SERVICE PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 POLYGEN GMBH
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 QIAGEN
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 QUINTARA BIOSCIENCES
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.20 TRILINK BIOTECHNOLOGIES, LLC
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
15.21 TWIST BIOSCIENCE
15.21.1 COMPANY SNAPSHOT
15.21.2 REVENEUE ANALYSIS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENTS
16 CONCLUSION
17 QUESTIONNAIRE
18 RELATED REPORTS